SutroVax Stock
SutroVax is a biopharmaceutical company
Sign up today and learn more about SutroVax Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About SutroVax Stock
SutroVax is a recently established biopharmaceutical company developing vaccines for infectious disease targets with an initial emphasis on best-in-class conjugate vaccines and protein-based vaccines. SutroVax is an independent company that was spun out of Sutro Biopharma with an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.
Funding History
| July 2015 | $22.0M |
|---|---|
| March 2017 | $4.0M |
| March 2017 | $60.0M |
| June 2018 | $85.0M |
Management
Chairman
Moncef Slaoui
Founder & CEO
Grant E. Pickering
Press
OutSourcing-Pharma.com - Jun, 12 2018
After raising $85m, SutroVax contracts Lonza to support vaccine developmentFierceBiotech - May, 25 2018
Pivotal bioVenture Partners debuts $150M China-focused biotech fundThe Pharma Letter - Mar, 7 2018
Analysts say cell-based and recombinant flu vaccines are the futurePR Newswire (press release) - Oct, 11 2017
SutroVax Appoints Veteran Vaccine Experts to Executive TeamPR Newswire (press release) - Jul, 19 2017
Dr. Moncef Slaoui, former GlaxoSmithKline Chairman of Vaccines, Appointed to SutroVax Board of DirectorsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
